| Unknown | A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock | Phase 2 | 2018-08-01 |
| Completed | A Study of LJPC-501 in Pediatric Patients With Hypotension Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock | Phase 2 | 2018-02-11 |
| Terminated | A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Bet Beta-Thalassemia | Phase 2 | 2017-11-30 |
| Completed | A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis Hereditary Hemochromatosis | Phase 2 | 2017-11-29 |
| Completed | A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock | Phase 3 | 2015-03-01 |
| Unknown | A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes Diabetic Chronic Kidney Disease | Phase 2 | 2015-03-01 |
| Withdrawn | A Phase 2 Extension of Study GCS-100-CS-4003 Chronic Kidney Disease | Phase 2 | 2015-01-01 |
| Terminated | A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome Hepatorenal Syndrome Type I and Type II | Phase 1 | 2014-03-01 |
| Completed | A Phase 2 Extension Study of Study GCS-100-CS-4002 Chronic Kidney Disease | Phase 2 | 2014-01-01 |
| Completed | A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease Chronic Kidney Disease | Phase 2 | 2013-06-01 |
| Completed | Safety Study of GCS-100 to Treat Chronic Kidney Disease Chronic Kidney Disease | Phase 1 | 2013-01-01 |
| Withdrawn | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymph Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | 2008-07-01 |
| Terminated | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma Multiple Myeloma | Phase 1 | 2008-05-01 |
| Completed | Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia | Phase 2 | 2007-02-01 |
| Withdrawn | Study of LJP 394 (Abetimus Sodium) in Lupus Patients Systemic Lupus Erythematosus | Phase 2 | 2006-09-01 |
| Terminated | Study of LJP 394 in Lupus Patients With History of Renal Disease Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 3 | 2004-10-01 |
| Completed | Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus | Phase 3 | — |
| Approved For Marketing | Expanded Access for LJPC-501 Catecholamine Resistant Hypotension (CRH), Distributive Shock, High Output Shock | — | — |